Brief: Qurient Announces Collaboration Agreement With MSD
14/09/2022 22:30
Sept 14 (Reuters) - Qurient Co Ltd 115180.KQ :
* QURIENT ANNOUNCES COLLABORATION AGREEMENT WITH MSD TO
EVALUATE
SELECTIVE CDK7 INHIBITOR Q901 IN COMBINATION WITH KEYTRUDA®
(PEMBROLIZUMAB)
* QURIENT CO LTD - Q901 IS READY FOR DOSE ESCALATION STUDY
IN U.S.
FOR TREATMENT OF SELECTED ADVANCED SOLID TUMORS (NCT05394103)
* QURIENT CO LTD - PHASE 1/2 STUDY OF Q901 AND KEYTRUDA IS
DESIGNED TO ENROLL PATIENTS WITH ADVANCED SOLID TUMORS
* QURIENT CO LTD- WILL CONDUCT A PHASE 1/2 STUDY IN U.S. TO
EVALUATE SAFETY AND EFFICACY OF Q901 IN COMBINATION WITH
KEYTRUDA
* QURIENT CO LTD - TERMS OF COLLABORATION WERE NOT DISCLOSED
Source text for Eikon: ID:nBw43vjSRa
Further company coverage: 115180.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Qurient
See all newsBrief: Lonza Expands Dual-Payload ADC Technology Offering Through Access To Qurient's CDK7 Inhibitors
Brief: Qurient To Conduct Capital Increase Of 8 Billion Won For Operational Funds
Brief: Qurient Therapeutics Enters Crada With The National Cancer Institute To Collaborate On A Phase 1/2 Clinical Study Of Q901 In Combination With Trop2-Adc
Brief: Qurient Announces Dosing Of First Patient In Q901 Phase 1/2 Clinical Study For The Treatment Of Patients With Solid Tumors
Brief: Qurient Announces Collaboration Agreement With MSD